Literature DB >> 21511200

Emerging targets and treatments in amyotrophic lateral sclerosis.

Lorne Zinman1, Merit Cudkowicz.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease that is currently untreatable. Many compounds have been tested in laboratory-based models and in patients with ALS, but so far only one drug, riluzole, has shown efficacy, yet it only slightly slows disease progression. Several new insights into the causes of motor neuron death have led to the identification of some important novel targets for intervention. At no time have studies involved such a wide range of innovations and such advanced technologies. Many promising studies are underway to test potential targets that will hopefully translate into meaningful therapeutics for patients with ALS.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21511200     DOI: 10.1016/S1474-4422(11)70024-2

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  35 in total

Review 1.  Neurodegeneration the RNA way.

Authors:  Abigail J Renoux; Peter K Todd
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

Review 2.  NSAIDs in the treatment and/or prevention of neurological disorders.

Authors:  Parto S Khansari; Leanne Coyne
Journal:  Inflammopharmacology       Date:  2012-01-10       Impact factor: 4.473

Review 3.  Does lithium prevent Alzheimer's disease?

Authors:  Orestes V Forlenza; Vanessa J de Paula; Rodrigo Machado-Vieira; Breno S Diniz; Wagner F Gattaz
Journal:  Drugs Aging       Date:  2012-05-01       Impact factor: 3.923

4.  A role for ubiquilin 2 mutations in neurodegeneration.

Authors:  Hussein Daoud; Guy A Rouleau
Journal:  Nat Rev Neurol       Date:  2011-10-11       Impact factor: 42.937

5.  Pseudo-ischaemic ECG in a patient with amyotrophic lateral sclerosis surviving for a decade.

Authors:  Jian Zhang; Shi-Wei Yang; Zheng Wang; Guang-Ru Wei; Yu-Jie Zhou
Journal:  BMJ Case Rep       Date:  2012-02-25

Review 6.  Moving forward in clinical trials for ALS: motor neurons lead the way please.

Authors:  Bariş Genç; P Hande Özdinler
Journal:  Drug Discov Today       Date:  2013-10-27       Impact factor: 7.851

7.  New Therapeutic Avenue for ALS: Avoiding a Fatal Encounter of TDP-43 at the Mitochondria.

Authors:  Eloise Hudry
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454

8.  Intermittent hypoxia and stem cell implants preserve breathing capacity in a rodent model of amyotrophic lateral sclerosis.

Authors:  Nicole L Nichols; Genevieve Gowing; Irawan Satriotomo; Lisa J Nashold; Erica A Dale; Masatoshi Suzuki; Pablo Avalos; Patrick L Mulcrone; Jacalyn McHugh; Clive N Svendsen; Gordon S Mitchell
Journal:  Am J Respir Crit Care Med       Date:  2012-12-06       Impact factor: 21.405

9.  Acute intermittent hypoxia induced phrenic long-term facilitation despite increased SOD1 expression in a rat model of ALS.

Authors:  Nicole L Nichols; Irawan Satriotomo; Daniel J Harrigan; Gordon S Mitchell
Journal:  Exp Neurol       Date:  2015-08-16       Impact factor: 5.330

Review 10.  The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier).

Authors:  Adam L Boxer; Michael Gold; Edward Huey; William T Hu; Howard Rosen; Joel Kramer; Fen-Biao Gao; Edward A Burton; Tiffany Chow; Aimee Kao; Blair R Leavitt; Bruce Lamb; Megan Grether; David Knopman; Nigel J Cairns; Ian R Mackenzie; Laura Mitic; Erik D Roberson; Daniel Van Kammen; Marc Cantillon; Kathleen Zahs; George Jackson; Stephen Salloway; John Morris; Gary Tong; Howard Feldman; Howard Fillit; Susan Dickinson; Zaven S Khachaturian; Margaret Sutherland; Susan Abushakra; Joseph Lewcock; Robert Farese; Robert O Kenet; Frank Laferla; Steve Perrin; Steve Whitaker; Lawrence Honig; Marsel M Mesulam; Brad Boeve; Murray Grossman; Bruce L Miller; Jeffrey L Cummings
Journal:  Alzheimers Dement       Date:  2012-10-10       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.